Comparative Pharmacology
Head-to-head clinical analysis: CHOLEDYL SA versus DILOR 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLEDYL SA versus DILOR 400.
CHOLEDYL SA vs DILOR-400
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Choledyl SA (theophylline, sustained-release) is a methylxanthine that inhibits phosphodiesterase, increasing intracellular cAMP, and blocks adenosine receptors, leading to bronchodilation and anti-inflammatory effects.
Phosphodiesterase inhibitor; inhibits PDE4 and PDE5, leading to increased intracellular cAMP and cGMP, resulting in bronchodilation and vasodilation.
400 mg orally every 12 hours (sustained-release); maximum 800 mg every 12 hours.
400 mg orally every 6 to 8 hours; maximum daily dose 2400 mg.
None Documented
None Documented
Terminal elimination half-life: 7-9 hours in healthy adults; prolonged in hepatic cirrhosis (up to 30 hours), heart failure, COPD, and in neonates; shortened in smokers and cystic fibrosis.
3.1 hours (terminal elimination half-life; may increase in hepatic impairment or congestive heart failure)
Renal: 90% as unchanged drug and metabolites (theophylline metabolites including 1,3-dimethyluric acid, 3-methylxanthine, and 1-methyluric acid). Biliary/fecal: <10%.
Renal (70% unchanged), hepatic metabolism (30%)
Category C
Category C
Bronchodilator
Bronchodilator